Clinical Trial Update: Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma

View source ↗

Summary

The expanded access program for nivolumab in combination with ipilimumab in patients with unresectable or metastatic malignant melanoma is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• OPDIVO (nivolumab)
• Yervoy (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Malignant Melanoma | Status: NO_LONGER_AVAILABLE